secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2023-05-23T23:59:59+00:00
Accession:  0001104659-23-063676
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PowerUp Acquisition extends deadline to May 2024; ~$283M redeemed from trust
----------------------------------------------------------------------------

- Shareholders approved extension of business combination deadline from May 23, 2023 to May 23, 2024.
- Approximately 26.95M public shares redeemed, removing ~$283M (≈$10.51/share) from trust; ~$20M remains.
- Following redemptions, only ~1.8M public shares outstanding (from ~28.75M pre-redemption).
- All 7,187,500 Class B shares converted to Class A on a one-for-one basis; no Class B shares remain.
- Post-conversion and redemptions, ~8.99M Class A shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000110465923063676/0001104659-23-063676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000110465923063676/tm2316603d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-063676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer